Atom Therapeutics

China Medical System Holdings (CMS; HKG: 0867) has entered into a licensing agreement with compatriot firm Atom Therapeutics, securing exclusive commercialization rights to ABP-671, a Category 1 chemical drug for gout and hyperuricemia, in mainland China, Hong Kong, and Macau. The financial specifics of the agreement were not disclosed. ABP-671:…